Status:
COMPLETED
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Assess that for an equivalent brachial blood pressure (BP)lowering, a fixed dose combination amlodipine/valsartan based regimen reduces central aortic BP pressure to a larger extent than an atenolol/a...
Eligibility Criteria
Inclusion
- Male or female patients 18 years of age or older
- Hypertension defined by MSDBP \> 90 and or MSSBP \> 140 mmHg, MSDBP \> 80 mmHg, or/and MSSBP \> 130 mmHg if diabetes or chronic renal impairment uncontrolled under their previous therapy, or untreated , or experiencing unacceptable side effects
- Written informed consent to participate in the study prior to any study procedures
Exclusion
- Severe hypertension (grade 3 WHO classification MSDBP \> 110 mmHg and/or MSSBP \> 180 mmHg)
- Evidence of a secondary form of hypertension
- Type 1 diabetes mellitus
- History of congestive heart failure, unstable coronary insufficiency, life threatening arrhythmia, significant valvular disease, second or third degree heart block etc.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
393 Patients enrolled
Trial Details
Trial ID
NCT00687973
Start Date
January 1 2008
End Date
January 1 2009
Last Update
March 11 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
2 & 4 rue Lionel Terray BP 308
Rueil-Malmaison, France, 92506